JP4399260B2 - 神経再生ペプチドおよび脳損傷治療におけるその使用方法 - Google Patents

神経再生ペプチドおよび脳損傷治療におけるその使用方法 Download PDF

Info

Publication number
JP4399260B2
JP4399260B2 JP2003523605A JP2003523605A JP4399260B2 JP 4399260 B2 JP4399260 B2 JP 4399260B2 JP 2003523605 A JP2003523605 A JP 2003523605A JP 2003523605 A JP2003523605 A JP 2003523605A JP 4399260 B2 JP4399260 B2 JP 4399260B2
Authority
JP
Japan
Prior art keywords
nrp
gly
ala
leu
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003523605A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511015A5 (enExample
JP2005511015A (ja
Inventor
フランク シーグ
ポール ヒューギース
Original Assignee
ニューレン ファーマシューティカルズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューレン ファーマシューティカルズ リミテッド filed Critical ニューレン ファーマシューティカルズ リミテッド
Publication of JP2005511015A publication Critical patent/JP2005511015A/ja
Publication of JP2005511015A5 publication Critical patent/JP2005511015A5/ja
Application granted granted Critical
Publication of JP4399260B2 publication Critical patent/JP4399260B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2003523605A 2001-08-24 2002-08-22 神経再生ペプチドおよび脳損傷治療におけるその使用方法 Expired - Fee Related JP4399260B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31495201P 2001-08-24 2001-08-24
PCT/US2002/026782 WO2003018754A2 (en) 2001-08-24 2002-08-22 Neural regeneration peptide and methods for their use in treatment of brain damage

Publications (3)

Publication Number Publication Date
JP2005511015A JP2005511015A (ja) 2005-04-28
JP2005511015A5 JP2005511015A5 (enExample) 2006-01-05
JP4399260B2 true JP4399260B2 (ja) 2010-01-13

Family

ID=23222205

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003523605A Expired - Fee Related JP4399260B2 (ja) 2001-08-24 2002-08-22 神経再生ペプチドおよび脳損傷治療におけるその使用方法

Country Status (5)

Country Link
US (2) US7767786B2 (enExample)
EP (2) EP2382982A3 (enExample)
JP (1) JP4399260B2 (enExample)
AU (1) AU2002335657A1 (enExample)
WO (1) WO2003018754A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60232880D1 (de) 2001-05-24 2009-08-20 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7605177B2 (en) * 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
DE602004029058D1 (de) * 2003-07-09 2010-10-21 Shinonogi & Co Ltd Inducer von atopischer dermatitis
EP1685151A4 (en) * 2003-10-31 2009-04-22 Neuren Pharmaceuticals Ltd PEPTIDES FOR THE REGENERATION OF NERVES AND METHOD FOR THEIR APPLICATION IN THE TREATMENT OF BRAIN DAMAGES
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
WO2006121926A2 (en) * 2005-05-06 2006-11-16 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods for their use
HRP20131016T1 (hr) 2007-10-17 2014-01-03 Curonz Holdings Company Limited Sintetiäśki analozi neuralnih regeneracijskih peptida
US9259432B1 (en) 2011-01-31 2016-02-16 Parminder J. S. Vig Composition and methods for targeted delivery of a therapeutic compound to the brain or spinal cord of a subject for treatment of neurodegenerative diseases
US20140018299A1 (en) * 2012-07-10 2014-01-16 Banyan Biomarkers, Inc. Method and device to detect, monitor and promote neural regeneration and improvement of cognitive function in a subject suffering from neural injury
BR112016007816A2 (pt) * 2013-10-11 2017-12-05 Tarix Pharmaceuticals Ltd composições peptídicas inovadoras
CN119080877B (zh) * 2024-10-11 2025-09-23 完美（广东）日用品有限公司 一种低聚肽及其在制备减脂制品中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3483949D1 (de) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
WO1995006662A1 (en) * 1993-09-01 1995-03-09 Start Technology Partnership Neuron regulatory factor for promoting neuron survival
EP0756494A1 (en) 1994-05-24 1997-02-05 Amgen Boulder Inc. Modified insulin-like growth factors
US5834192A (en) 1996-04-05 1998-11-10 Incyte Pharmaceuticals, Inc. Human cachexia associated protein
WO1998011136A1 (en) 1996-09-09 1998-03-19 Novo Nordisk A/S A cDNA AND PEPTIDE WITH RELATION TO CANCER AND WEIGHT LOSS
HUP0100668A3 (en) * 1997-11-25 2005-01-28 Gen Hospital Corp Boston Virulence-associated nucleic sequences and uses thereof
AU3221399A (en) * 1998-04-03 1999-10-25 Mcp Hahnemann University Neuron regulatory factor comprising a small peptide for promoting neuron survival
US7563862B2 (en) * 2001-08-24 2009-07-21 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods for their use in treatment of brain damage

Also Published As

Publication number Publication date
AU2002335657A8 (en) 2008-01-10
EP2382982A3 (en) 2012-02-22
US7767786B2 (en) 2010-08-03
EP1572887A4 (en) 2008-12-24
US20030211990A1 (en) 2003-11-13
WO2003018754A2 (en) 2003-03-06
WO2003018754A3 (en) 2007-11-15
EP2382982A2 (en) 2011-11-02
EP1572887A2 (en) 2005-09-14
US20110306557A1 (en) 2011-12-15
AU2002335657A1 (en) 2003-03-10
JP2005511015A (ja) 2005-04-28

Similar Documents

Publication Publication Date Title
US7563862B2 (en) Neural regeneration peptides and methods for their use in treatment of brain damage
US20110306557A1 (en) Neural regeneration peptides and methods for their use in treatment of brain damage
US8680239B2 (en) Use of RGM and its modulators
CA2133443A1 (en) Cloning, expression and uses of a novel secreted protein, f-spondin
US6262024B1 (en) Neuron regulatory factor for promoting neuron survival
WO1998022499A9 (en) Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof
WO1998022499A2 (en) Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof
JPH07509600A (ja) ニューロトロフィン−４発現に基づく治療および診断法
JP2005511015A5 (enExample)
JP2004528835A (ja) ドーパミン作動性ニューロン生存促進因子およびその用途
JP5026083B2 (ja) 神経再生ペプチド及び脳損傷治療におけるそれらの使用方法
JP4988711B2 (ja) 神経再生ペプチド及びそれを含む処方物
AU2002363524B2 (en) Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof
AU693207B2 (en) A novel brain endothelial cell protein and methods for its use
JP2002509693A (ja) カドヘリン由来成長因子及びその使用
AU2002363524A1 (en) Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof
CA2372559A1 (en) Neurite outgrowth and guidance by tenascin-c
WO1997040155A1 (en) Protein mediating neuronal-glial interaction, dna encoding the same, and methods of use thereof
JP2002514386A (ja) ヒトｆｇｆ遺伝子および遺伝子発現産物
JP2004517917A (ja) 星状細胞及び星状細胞性腫瘍細胞の増殖を阻害する方法とその使用
WO2004001038A1 (ja) 細胞または組織の神経化に関与する新規遺伝子およびタンパク質、並びにその利用
CA2221391A1 (en) Neuron and neural tumour growth regulatory system, antibodies thereto and uses thereof
JPH10201477A (ja) 蛋白質ｓａｐａｐ１

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060427

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090616

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090916

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091019

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091026

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121030

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121030

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121030

Year of fee payment: 3

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D03

LAPS Cancellation because of no payment of annual fees